The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Open accessAbstract
BACKGROUND: Intratumor heterogeneity may foster tumor evolution and adaptation and hinder personalized-medicine strategies that depend on results from single tumor-biopsy samples. METHODS: To examine intratumor heterogeneity, we performed exome sequencing, chromosome aberration analysis, and ploidy profiling on multiple spatially separated samples obtained from primary renal carcinomas and associated metastatic sites. We characterized the consequences of intratumor heterogeneity using immunohistochemical analysis, mutation functional analysis, and profiling of messenger RNA expression. RESULTS: Phylogenetic reconstruction revealed branched evolutionary tumor growth, with 63 to 69% of all somatic mutations not detectable across every tumor region. Intratumor heterogeneity was observed for a mutation within an autoinhibitory domain of the mammalian target of rapamycin (mTOR) kinase, correlating with S6 and 4EBP phosphorylation in vivo and constitutive activation of mTOR kinase activity in vitro. Mutational intratumor heterogeneity was seen for multiple tumor-suppressor genes converging on loss of function; SETD2, PTEN, and KDM5C underwent multiple distinct and spatially separated inactivating mutations within a single tumor, suggesting convergent phenotypic evolution. Gene-expression signatures of good and poor prognosis were detected in different regions of the same tumor. Allelic composition and ploidy profiling analysis revealed extensive intratumor heterogeneity, with 26 of 30 tumor samples from four tumors harboring divergent allelic-imbalance profiles and with ploidy heterogeneity in two of four tumors. CONCLUSIONS: Intratumor heterogeneity can lead to underestimation of the tumor genomics landscape portrayed from single tumor-biopsy samples and may present major challenges to personalized-medicine and biomarker development. Intratumor heterogeneity, associated with heterogeneous protein function, may foster tumor adaptation and therapeutic failure through Darwinian selection. (Funded by the Medical Research Council and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A greater degree of divergence may be attributed to intra-tumor spatial heterogeneity and sampling bias: tumors can be spatially diverse, and organoids generated from a specific portion may lack the representativeness of distant regions130,131.”
From Organoids (2022) · cites this paper as [130]
Experimental — accuracy not yet measuredIn the citing paper
“a small needle biopsy of a single lesion may fail to reflect the true underlying intra- and inter-tumor genetic heterogeneity (15–17).”
In the citing paper
“It is now appreciated that most clinically relevant solid tumors are highly heterogeneous at the phenotypic, physiologic, and genomic levels (13–15) and that they continue to evolve over time.”
From Radiomics: Images Are More than Pictures, They Are Data (2016) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Tumour evolution inferred by single-cell sequencing
Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, A., Levy, D., Esposito, D., et al. (2011) · Nature · doi:10.1038/nature09807 · Cited by 2,598
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Cancer as an evolutionary and ecological process
Merlo, L. M. F., Pepper, J. W., Reid, B. J., & Maley, C. C. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2013 · Cited by 1,743
Flanigan, R. C., Salmon, S. E., Blumenstein, B. A., Bearman, S. I., Roy, V., McGrath, P. C., Caton, J. R., Munshi, N. C., & Crawford, E. D. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003013 · Cited by 1,710
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,049
Carcinoma-associated fibroblasts provide operational flexibility in metastasis
Wever, O. D., Bockstal, M. V., Mareel, M., Hendrix, A., & Bracke, M. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.12.009 · Cited by 137
Montermini, L., Meehan, B., Garnier, D., Lee, W.-J., Lee, T., Guha, A., Al-Nedawi, K., & Rak, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.679217 · Cited by 121
“However, targeted therapy choices are presently imprecise, being extrapolated mainly from a one-time (static) access to treatment-naive tissues collected at surgery or biopsy (1, 13).”
BackgroundAllogeneic tumor cell vaccines
Srivatsan, S. R., Patel, J. M., Bozeman, E. N., Imasuen, I., He, S., Daniels, D., & Selvaraj, P. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.26568 · Cited by 133
The epigenetic landscape of renal cancer
Morris, M. R., & Latif, F. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.168 · Cited by 129
Hsieh, J. J.-D., Le, V., Cao, D., Cheng, E. H. Y., & Creighton, C. J. (2017) · The Journal of Pathology · doi:10.1002/path.5022 · Cited by 131
Deciphering Tumour Heterogeneity: From Tissue to Liquid Biopsy
Gilson, P., Merlin, J., & Harlé, A. (2022) · Cancers · doi:10.3390/cancers14061384 · Cited by 138
Acquired resistance in cancer: towards targeted therapeutic strategies
Soragni, A., Knudsen, E. S., O’Connor, T. N., Tognon, C. E., Tyner, J. W., Gini, B., Kim, D., Bivona, T. G., Zang, X., Witkiewicz, A. K., et al. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00824-9 · Cited by 151
“Tumours have highly heterogeneous genomic landscapes, wherein clonal and subclonal cell populations with distinct mutational, genomic copy number patterns or epigenetic features contribute to disease progression and to the acquisition of drug resistance 2–4 .”
Werner, S. L., Graf, R. P., Landers, M. A., Valenta, D. T., Schroeder, M. J., Greene, S. B., Bales, N., Dittamore, R. V., & Marrinucci, D. C. (2015) · Journal of Circulating Biomarkers · doi:10.5772/60725 · Cited by 131
Mossner, M., Jann, J.-C., Wittig, J., Nolte, F., Fey, S., Nowak, V., Obländer, J., Pressler, J., Palme, I., Xanthopoulos, C., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679167 · Cited by 135
Zhang, J., Späth, S. S., Marjani, S. L., Zhang, W., & Pan, X. (2018) · Precision Clinical Medicine · doi:10.1093/pcmedi/pby007 · Cited by 137
“Genomic profiling technology, that is genome-wide next-generation sequencing (NGS), is increasingly used to uncover different aspects of genomic heterogeneity in many types of human diseases, including cancer.(9,10) The Cancer Genome Atlas (TCGA) project was a comprehensive and coordinated effort to accelerate our und…”
BackgroundCT texture analysis of pancreatic cancer
Sandrasegaran, K., Lin, Y., Asare-Sawiri, M., Taiyini, T., & Tann, M. A. (2018) · European Radiology · doi:10.1007/s00330-018-5662-1 · Cited by 128
A clonal expression biomarker associates with lung cancer mortality
Biswas, D., Birkbak, N. J., Rosenthal, R., Hiley, C. T., Lim, E. L., Papp, K., Boeing, S., Krzystanek, M., Djureinovic, D., Fleur, L. L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0595-z · Cited by 128
Self-citationmiRNA Gene Promoters Are Frequent Targets of Aberrant DNA Methylation in Human Breast Cancer
Vrba, L., Muñoz-Rodríguez, J. L., Stampfer, M. R., & Futscher, B. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054398 · Cited by 129
Emerging technologies in extracellular vesicle-based molecular diagnostics
Jia, S., Zocco, D., Samuels, M. L., Chou, M. F., Chammas, R. J., Skog, J., Zarovni, N., Momen‐Heravi, F., & Kuo, W. P. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.893828 · Cited by 127
How can attrition rates be reduced in cancer drug discovery?
Moreno, L., & Pearson, A. D. J. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.768984 · Cited by 127
De novo discovery of phenotypic intratumour heterogeneity using imaging mass spectrometry
Balluff, B., Frese, C. K., Maier, S. K., Schöne, C., Küster, B., Schmitt, M., Aubele, M. M., Höfler, H., Deelder, A. M., Heck, A. J. R., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4436 · Cited by 128
Gao, Q., Wang, Z.-C., Duan, M., Lin, Y.-H., Zhou, X., Worthley, D. L., Wang, X.-Y., Niu, G., Xia, Y., Deng, M., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.09.008 · Cited by 128
Radiomics in Oncological PET/CT: a Methodological Overview
Ha, S., Choi, H., Paeng, J. C., & Cheon, G. J. (2019) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-019-00571-4 · Cited by 129
Tijhuis, A. E., Johnson, S. C., & McClelland, S. E. (2019) · Molecular Cytogenetics · doi:10.1186/s13039-019-0429-1 · Cited by 131
“This might be due to the nature of ITH itself, as the presence of multiple subclones makes it more laborious to gather reliable clinical data from a limited number of biopsies per patient [91, 164].”
BackgroundMultiplexed imaging in oncology
Andreou, C., Weissleder, R., & Kircher, M. F. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00891-5 · Cited by 132
TrAp: a tree approach for fingerprinting subclonal tumor composition
Strino, F., Parisi, F., Micsinai, M., & Kluger, Y. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt641 · Cited by 126
Can nanomedicines kill cancer stem cells?
Zhao, Y., Alakhova, D. Y., & Kabanov, A. V. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.016 · Cited by 129
Kelley, R. K., Magbanua, M. J. M., Butler, T. M., Collisson, E. A., Hwang, J. J., Sidiropoulos, N., Evason, K. J., McWhirter, R. M., Hameed, B., Wayne, E. M., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1195-z · Cited by 125
“The advent of next-generation sequencing has revealed a remarkable degree of heterogeneity within individual tumors and between primary tumors and their metastases [39].”
Grade Heterogeneity in Small Renal Masses: Potential Implications for Renal Mass Biopsy
Ball, M. W., Bezerra, S. M., Gorin, M. A., et al. (2014) · The Journal of Urology · doi:10.1016/j.juro.2014.06.067 · Cited by 125
A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma
Wei, J., Haddad, A., Wu, K.-J., Zhao, H.-W., Kapur, P., Zhang, Z.-L., Zhao, L.-Y., Chen, Z., Zhou, Y.-Y., Zhou, J.-C., et al. (2015) · Nature Communications · doi:10.1038/ncomms9699 · Cited by 128
Gay, L. J., Baker, A., & Graham, T. A. (2016) · F1000Research · doi:10.12688/f1000research.7210.1 · Cited by 129
DNA methylation based biomarkers in colorectal cancer: A systematic review
Lam, K., Pan, K., Linnekamp, J. F., Medema, J. P., & Kandimalla, R. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.07.001 · Cited by 125
“colorectal and other cancers, suggesting its major impact on biomarker development [116,117].”
Smith, C. G., Moser, T., Burge, J., Eldridge, M., Riediger, A. L., Mouliere, F. C., Chandrananda, D., Heider, K., Wan, J. C. M., Warren, A. Y., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-00723-8 · Cited by 126
“These included the genes VHL, PBRM1, and SETD2 [2].”
BackgroundMethodInfluentialOvercoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
Spagnolo, F., Ghiorzo, P., & Queirolo, P. (2014) · Oncotarget · doi:10.18632/oncotarget.2602 · Cited by 128
Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer
Weiss, A., Ding, X., B, J. R. V. B., Wong, I., Wong, T. J., Berndsen, R. H., Dormond, O., Dallinga, M. G., Shen, L., Schlingemann, R. O., et al. (2015) · Angiogenesis · doi:10.1007/s10456-015-9462-9 · Cited by 122
“Their contribution to the prolongation of patient survival, however, is often limited mainly due to disease and patient heterogeneity [4, 5], toxicity [6], induction of metastasis [7] and drug resistance [8, 9].”
BackgroundBiopsies: next-generation biospecimens for tailoring therapy
Basik, M., Aguilar‐Mahecha, A., Rousseau, C., Diaz, Z., Tejpar, S., Spatz, A., Greenwood, C. M. T., & Batist, G. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.101 · Cited by 126
Next generation sequencing in cancer research and clinical application
Shyr, D., & Liu, Q. (2013) · Biological Procedures Online · doi:10.1186/1480-9222-15-4 · Cited by 130
Jovelet, C., Ileana, E. E., Deley, M. L., Motté, N., Rosellini, S., Romero, A., Lefèbvre, C., Pedrero, M., Pata-Merci, N., Droin, N. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2470 · Cited by 132
“However, biopsy techniques present ethical and logistic challenges, due to their invasiveness, morbidity, cost, variable accessibility of the tumor sites, as well as potential sampling bias due to intratumor genetic heterogeneity (6,7).”
BackgroundTargeted therapies for gastric cancer: failures and hopes from clinical trials
Apicella, M., Corso, S., & Giordano, S. (2017) · Oncotarget · doi:10.18632/oncotarget.14825 · Cited by 126
“Ideally, the problem of intratumor heterogeneity could be overcome targeting “trunk” mutations, that is somatic alterations driving tumor growth, already present in early clonal progenitors and ubiquitously present at all sites of disease [97].”
BackgroundIbrahim‐Hashim, A., Robertson‐Tessi, M., Enríquez‐Navas, P. M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2844 · Cited by 124
“Several recent studies have demonstrated multiple genetically-distinct populations within human cancers (3, 4) as a result of ongoing evolution.”
Konen, J. M., Summerbell, E. R., Dwivedi, B., Galior, K. D., Hou, Y., Rusnak, L., Chen, A., Saltz, J. H., Zhou, W., Boise, L., et al. (2017) · Nature Communications · doi:10.1038/ncomms15078 · Cited by 124
“Genomic instability and epigenetic modifications generate intratumor heterogeneity 2–7 creating distinct genetic and epigenetic subpopulations or clones 5,8–11 .”
BackgroundChromosomal Instability in Tumor Initiation and Development
Bach, D., Zhang, W., & Sood, A. K. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3235 · Cited by 133
“High levels of aneuploidy and tetraploidy have also been generally associated with the generation of metastases (75, 76).”
Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients
Marzese, D. M., Hirose, H., & Hoon, D. S. �. (2013) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2013.845088 · Cited by 123
Concomitant RAS , RET/PTC , or BRAF Mutations in Advanced Stage of Papillary Thyroid Carcinoma
Zou, M., Baitei, E. Y., Alzahrani, A. S., et al. (2014) · Thyroid · doi:10.1089/thy.2013.0610 · Cited by 123
Lorz, A., Lorenzi, T., Clairambault, J., Escargueil, A. E., & Benoît Perthame, B. (2014) · Bulletin of Mathematical Biology · doi:10.1007/s11538-014-0046-4 · Cited by 137
Wang, K., Russell, J. S., McDermott, J. D., Elvin, J. A., Khaira, D., Johnson, A., Jennings, T. A., Ali, S. M., Murray, M., Marshall, C. B., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2568 · Cited by 123
“Recent studies in renal cell and lung cancers have demonstrated that different clones have varying driver mutations whose importance can fluctuate over time (49, 50).”
BackgroundCancer epigenetics: Past, present and future
Lee, J. E., & Kim, M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.025 · Cited by 132
Dynamics of Tumor Heterogeneity Derived from Clonal Karyotypic Evolution
Laughney, A. M., Elizalde, S., Genovese, G., & Bakhoum, S. F. W. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.065 · Cited by 120
Biobanking 3.0: Evidence based and customer focused biobanking
Simeon‐Dubach, D., & Watson, P. H. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2013.12.018 · Cited by 123
Peña‐Llopis, S., & Brugarolas, J. (2013) · Nature Protocols · doi:10.1038/nprot.2013.141 · Cited by 122
Cell‐free circulating tumour DNA as a liquid biopsy in breast cancer
Mattos‐Arruda, L. D., & Caldas, C. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.12.001 · Cited by 124
Single-Cell Sequencing for Precise Cancer Research: Progress and Prospects
Zhang, X., Marjani, S. L., Hu, Z., Weissman, S. M., Pan, X., & Wu, S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1907 · Cited by 122
“Cancer cells dispersed in an individual or even forming a single tumor or a clone are often heterogeneous, and this heterogeneity changes dynamically with disease progression (4).”
BackgroundVargas, H. A., Veeraraghavan, H., Miccò, M., Nougaret, S., Lakhman, Y., Meier, A. A., Sosa, R. E., Soslow, R. A., Levine, D. A., Weigelt, B., et al. (2017) · European Radiology · doi:10.1007/s00330-017-4779-y · Cited by 121
Integration of phytochemicals and phytotherapy into cancer precision medicine
Efferth, T., Saeed, M. E. M., Mirghani, E., Alim, A., Yassin, Z., Saeed, E. M., Khalid, H. E., & Daak, S. (2017) · Oncotarget · doi:10.18632/oncotarget.17466 · Cited by 125
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)
Gouda, M. A., Jankú, F., Wahida, A., Buschhorn, L., Schneeweiß, A., Karim, N. A., de Miguel‐Pérez, D., Re, M. D., Russo, A., Curigliano, G., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.12.007 · Cited by 120
Kovac, M. B., Navas, C., Horswell, S. D., Salm, M., Bardella, C., Rowan, A., Stares, M., Castro-Giner, F., Fisher, R. A., de Bruin, E. C., et al. (2015) · Nature Communications · doi:10.1038/ncomms7336 · Cited by 123
Self-citationSankin, A. I., Hakimi, A. A., Mikkilineni, N., Ostrovnaya, I., Silk, M. T., Liang, Y., Mano, R., Chevinsky, M. S., Motzer, R. J., Solomon, S. B., et al. (2014) · Cancer Medicine · doi:10.1002/cam4.293 · Cited by 127
Gaykema, S. B. M., Schröder, C. P., Vitfell-Rasmussen, J., Chua, S. C., Munnink, T. H. O., Brouwers, A. H., Bongaerts, A. H. H., Akimov, M., Fernandez‐Ibarra, C., Hooge, M. N. L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0491 · Cited by 121
Self-citationThe isolation and characterization of CTC subsets related to breast cancer dormancy
Vishnoi, M., Peddibhotla, S., Yin, W., Scamardo, A. T., George, G. C., Hong, D. S., & Marchetti, D. (2015) · Scientific Reports · doi:10.1038/srep17533 · Cited by 125
Chen, K., Lou, F., Yang, F., Zhang, J., Ye, H., Chen, W., Guan, T., Zhao, M.-Y., Su, X.-X., Shi, R., et al. (2016) · Scientific Reports · doi:10.1038/srep31985 · Cited by 122
The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma
Mishima, Y., Paiva, B., Shi, J., Park, J., Manier, S., Takagi, S., Massoud, M. R., Perilla-Glen, A., Aljawai, Y. M., Huynh, D., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.025 · Cited by 119
“Even though intertumoral heterogeneity has been already described when sequencing two tumor biopsies from the same patient (Gerlinger et al., 2012), we believe that the discrepancy could also be driven by the effect of whole-genome amplification in some of the samples.”
BackgroundInfluentialAdenosquamous carcinoma of the lung
Li, C., & Lu, H. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s164574 · Cited by 125
“Occurrence of intratumoral gene mutations of monoclonal origin can be compared to growth of the trees, which in the beginning only have trunks and then branches continue to constantly grow out.(30) Driver mutations tend to be in the trunk of neoplastic evolutionary tree, whereas passenger mutations in the branch.”
Recent developments in genetic/genomic medicine
Horton, R. H., & Lucassen, A. (2019) · Clinical Science · doi:10.1042/cs20180436 · Cited by 124
Parseghian, C. M., Napolitano, S., Loree, J. M., & Kopetz, S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0823 · Cited by 124
“7 mechanisms of resistance that drive tumor progression (Figure 2).(50,51) These data suggest that”
BackgroundBashraheel, S. S., Dömling, A. S. S., & Goda, S. K. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110009 · Cited by 128
Zaccaria, S., & Raphael, B. J. (2020) · Nature Communications · doi:10.1038/s41467-020-17967-y · Cited by 113
Targeted therapy in metastatic colorectal cancer – An example of personalised medicine in action
Heinemann, V., Douillard, J., Ducreux, M. P., & Peeters, M. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.12.011 · Cited by 126
Extracellular vesicle communication pathways as regulatory targets of oncogenic transformation
Choi, D., Lee, T. H., Spinelli, C., Chennakrishnaiah, S., D’Asti, E., & Rak, J. W. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.01.003 · Cited by 121
The impact of proliferation-migration tradeoffs on phenotypic evolution in cancer
Gallaher, J., Brown, J. S., & Anderson, A. (2019) · Scientific Reports · doi:10.1038/s41598-019-39636-x · Cited by 112
Li, B., Zhang, B., Wang, X., Zeng, Z., Huang, Z., Zhang, L., Wei, F., Ren, X., & Yang, L. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1807291 · Cited by 118
Fraser, M. E., Berlín, A., Bristow, R. G., & van der Kwast, T. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.10.020 · Cited by 123
Pailler, E., Auger, N., Lindsay, C. R., Vielh, P. R., Islas-Morris-Hernandez, A., Borget, I., Ngo‐Camus, M., Planchard, D., Soria, J., Besse, B., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv165 · Cited by 123
“Recent pioneering studies have shown differences in tumor mutational profiles within distinct regions of the primary tumor and respective metastases, demonstrating intratumor heterogeneity in both space and time [9].”
BackgroundAnti-angiogenesis target therapy for advanced osteosarcoma
Xie, L., Ji, T., & Guo, W. (2017) · Oncology Reports · doi:10.3892/or.2017.5735 · Cited by 119
“Sorafenib TKIs veGfR-2 (90), Raf-1 (6), B-Raf (22), (15,16,35,70,71,86)”
BackgroundGenomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma
Araf, S., Wang, J., Korfi, K., Pangault, C., Kotsiou, E., Rio‐Machín, A., Rahim, T., Heward, J. A., Clear, A. J., Iqbal, S., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0043-y · Cited by 132
“precision-medicine-based strategies to care [8].”
Zhao, H., Yao, W., Min, X., Gu, K., Yu, G., Zhang, Z., Cui, J., Miao, L., Zhang, L., Yuan, X., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.05.006 · Cited by 123
An Epigenetic Role of Mitochondria in Cancer
Liu, Y., Chen, C., Wang, X., Sun, Y., Zhang, J., Chen, J., & Shi, Y. (2022) · Cells · doi:10.3390/cells11162518 · Cited by 131
Kast, R. E., Karpel‐Massler, G., & Halatsch, M. (2014) · Oncotarget · doi:10.18632/oncotarget.2408 · Cited by 121
Tapping CD4 T Cells for Cancer Immunotherapy: The Choice of Personalized Genomics
Zanetti, M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402669 · Cited by 133
Going with the Flow: From Circulating Tumor Cells to DNA
Bidard, F., Weigelt, B., & Reis-Filho, J. S. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006305 · Cited by 123
Microscopic lymph node tumor burden quantified by macroscopic dual-tracer molecular imaging
Tichauer, K. M., Samkoe, K. S., Gunn, J. R., Kanick, S. C., Hoopes, P. J., Barth, R. J., Kaufman, P. A., Hasan, T. G., & Pogue, B. W. (2014) · Nature Medicine · doi:10.1038/nm.3732 · Cited by 118
Speicher, M. R., & Pantel, K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2897 · Cited by 118
Emerging Understanding of Multiscale Tumor Heterogeneity
Gerdes, M. J., Sood, A., Sevinsky, C. J., Pris, A. D., Zavodszky, M. I., & Ginty, F. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00366 · Cited by 125
Quantifying tumor heterogeneity in whole-genome and whole-exome sequencing data
Oesper, L., Satas, G., & Raphael, B. J. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu651 · Cited by 114
Buttitta, F., Felicioni, L., Grammastro, M. D., Filice, G., Lorito, A. D., Malatesta, S., Viola, P., Centi, I., D’Antuono, T., Zappacosta, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1958 · Cited by 118
The fidelity of cancer cells in PDX models: Characteristics, mechanism and clinical significance
Shi, J., Li, Y., Jia, R., & Fan, X. (2019) · International Journal of Cancer · doi:10.1002/ijc.32662 · Cited by 120
“ITH dictates that there are different subtypes of each type of cancer based on distinct patterns of molecular and clinical features.(53) The engraftment rate of PDX tumors is associated with overall survival (OS), recurrence-free survival (RFS), diseasefree survival, stage, tumor subtype and other clinical features of…”
BackgroundEttrich, T. J., Schwerdel, D., Dolnik, A., Beuter, F., Blätte, T. J., Schmidt, S. A., Stanescu-Siegmund, N., Steinacker, J., Marienfeld, R. B., Kleger, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-49860-0 · Cited by 120
Liquid Biopsy in Breast Cancer: A Focused Review
Tay, T. K. Y., & Tan, P. H. (2020) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2019-0559-ra · Cited by 125
The Tubulin Code, from Molecules to Health and Disease
McKenna, E. D., Sarbanes, S. L., Cummings, S. W., & Roll‐Mecak, A. (2023) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-030123-032748 · Cited by 115
Saunus, J. M., Quinn, M. C. J., Patch, A., Pearson, J. V., Bailey, P. J., Nones, K., Reed, A. E. M., Miller, D. K., Wilson, P. J., Al‐Ejeh, F., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4583 · Cited by 121
“and phenotypically heterogeneous primary tumours [16-18].”
ResultDave, B., Granados-Principal, S. M., Zhu, R., Benz, S. C., Rabizadeh, S., Soon‐Shiong, P., Yu, K., Shao, Z., Li, X., Gilcrease, M. Z., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320769111 · Cited by 122
Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges
Dienstmann, R., Rodon, J. A., Barretina, J., & Tabernero, J. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2268 · Cited by 120
Intratumour Heterogeneity in Urologic Cancers: From Molecular Evidence to Clinical Implications
Gerlinger, M., Catto, J. W. F., Orntoft, T. F., Real, F. X., Zwarthoff, E. C., & Swanton, C. (2014) · European Urology · doi:10.1016/j.eururo.2014.04.014 · Cited by 124
“Multiregion exome sequencing revealed that the mutational landscapes of two metastases were much more similar to each other than to the primary tumour in one patient [18].”
BackgroundSelf-citationCiardiello, F., Normanno, N., Maiello, E., Martinelli, E., Troiani, T., Pisconti, S., Giuliani, F., Barone, C., Cartenì, G., Rachiglio, A. M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu230 · Cited by 116
Molecular Pathology of Non–Small Cell Lung Cancer
Aisner, D. L., & Marshall, C. B. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcpfr12wjkceezz · Cited by 119
Lu, L., Lv, W., Jiang, J., Ma, J., Feng, Q., Rahmim, A., & Chen, W. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-0973-6 · Cited by 117
Non-blood circulating tumor DNA detection in cancer
Peng, M., Chen, C., Hulbert, A., Brock, M. V., & Yu, F. (2017) · Oncotarget · doi:10.18632/oncotarget.19942 · Cited by 119
Crosstalk between the Warburg effect, redox regulation and autophagy induction in tumourigenesis
Gwangwa, M. V., Joubert, A. M., & Visagie, M. H. (2018) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-018-0088-y · Cited by 120
“The significant intra-tumour heterogeneity in tumour tissue plays an essential role in resistance to conventional anticancer treatments including chemotherapy and radiation [93].”
BackgroundLi, J., Han, X., Yu, X., Xu, Z., Yang, G., Liu, B., & Xiu, P. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0893-1 · Cited by 118
Kohsaka, S., Petronczki, M. P., Solca, F., & Maemondo, M. (2018) · Future Oncology · doi:10.2217/fon-2018-0736 · Cited by 123
“While the concept of tumor evolution has been accepted for a long time, it is only with recent technological advances, such as next-generation sequencing (NGS) platforms, that it has been possible to dissect the development of tumors at sufficient resolution to enable the construction of divergence-based phylogenetic…”
BackgroundChae, Y. K., Davis, A. A., Agte, S., Pan, A. P., Simon, N. I., Iams, W. T., Cruz, M. R. D. S., Tamragouri, K., Rhee, K., Mohindra, N. A., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0433 · Cited by 118
“Multiple prior studies have demonstrated mutational subclonality as a biomarker associated with poor survival [48, 49].”
BackgroundSingle cell analysis of cancer genomes
Loo, P. V., & Voet, T. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.12.004 · Cited by 118
Aisner, D. L., Nguyen, T. T., Paskulin, D. D., Le, A. T., Haney, J., Schulte, N., Chionh, F. J. M., Hardingham, J. E., Mariadason, J. M., Tebbutt, N. C., et al. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0479-t · Cited by 119
Medical treatment of renal cancer: new horizons
Greef, B., & Eisen, T. G. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.230 · Cited by 114
“…may affect the biology of tumours is not understood, but it is interesting to note that in an assessment of tumour heterogeneity in ccRCC by Gerlinger et al (2012) found three different mutations in SETD2 in different metastatic loci, suggesting a role for these mutations as secondary…”
BackgroundResultInfluentialThe role of molecular enrichment on future therapies in hepatocellular carcinoma
Nault, J., Galle, P. R., & Marquardt, J. U. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.02.016 · Cited by 117
Ytre‐Hauge, S., Dybvik, J. A., Lundervold, A., Salvesen, Ø. O., Krakstad, C., Fasmer, K. E., Werner, H. M. J., Ganeshan, B., Høivik, E. A., Bjørge, L., et al. (2018) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26184 · Cited by 116
“Mechanisms proposed to explain the aggressive behavior of heterogeneous tumors include Darwinian selection among clones enabling tumor adaptation and drug resistance.(3) Texture analysis (TA), a method for quantification of heterogeneity in images, has become an important element in the growing field of radiomics, the…”
Method
Metadata
- Authors
- Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., Varela, I., Phillimore, B., Begum, S., McDonald, N. Q., Butler, A., Jones, D., Raine, K., Latimer, C., Santos, C. R., Nohadani, M., Eklund, A. C., Spencer-Dene, B., Clark, G., Pickering, L., Stamp, G., Gore, M., Szallasi, Z., Downward, J., Futreal, P. A., & Swanton, C.
- Affiliations
- Queen Mary University of London (GB)
- ORCID
- Gerlinger, Marco
- Rowan, Andrew J.
- Horswell, Stuart
- Larkin, James
- Endesfelder, David
- Gronroos, Eva
- Martinez, Pierre
- Tarpey, Patrick
- Varela, Ignacio
- Begum, Sharmin
- McDonald, Neil Q.
- Jones, David
- Raine, Keiran
- Latimer, Calli
- Eklund, Aron C.
- Pickering, Lisa
- Stamp, Gordon
- Downward, Julian
- Futreal, P. Andrew
- Swanton, Charles
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-03-08
- Volume
- 366
- Issue
- 10
- Pages
- 883-892
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4878653
- OpenAlex
- W2150575159
- Semantic Scholar
- b97108a8e1dd8cf67ff9f374a8237fabf4c96ad4
- Cited by
- 7,774
- References
- 35
- Citations by year
- 2026: 304 · 2025: 297 · 2024: 306 · 2023: 349 · 2022: 499 · 2021: 571 · 2020: 550 · 2019: 540 · 2018: 632 · 2017: 671 · 2016: 722 · 2015: 691 · 2014: 679 · 2013: 621 · 2012: 326
- FWCI
- 246.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU) (submittedVersion)
- Funders
- Wellcome Trust (079643)
- Cancer Research UK (10747, 15680)
- National Institute for Health and Care Research
- Medical Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- intratumoral heterogeneity, tumor evolution, renal carcinoma, metastatic renal cell carcinoma, phylogenetic inference, mTOR, SETD2, PTEN, KDM5C, tumor suppressor mutations, allelic imbalance, aneuploidy, gene expression signatures, biomarker development, personalized medicine
- MeSH terms
- Everolimus, Biopsy, Carcinoma, Renal Cell, Chromosome Aberrations, Humans, Immunosuppressive Agents, Kidney, Kidney Neoplasms, Mutation, Neoplasm Metastasis, Phenotype, Phylogeny, Ploidies, Biomarkers, Tumor, Sequence Analysis, DNA, Genetic Heterogeneity, Evolution, Molecular, Sirolimus, Polymorphism, Single Nucleotide, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
